The role of radiotherapy in the multimodal management of esophageal cancer

Digestive Diseases

Volumn 31, Issue 1, 2013, Pages 30-37

  Fokas, Emmanouil ^a   Weiss, Christian ^a   Rödel, Claus ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Chemoradiotherapy; Esophageal cancer; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMORADIOTHERAPY; CONFERENCE PAPER; ESOPHAGUS CANCER; HUMAN; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURGICAL MORTALITY;

EID: 84879575939     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000347170     Document Type: Conference Paper

References (46)

1. Pennathur A, Luketich JD: Resection for esophageal cancer: strategies for optimal management. Ann Thorac Surg 2008; 85: S751-S756.
2. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317.
3. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-1168.
4. Gray JR, Hainsworth JD, Meluch AA, et al: Concurrent paclitaxel/carboplatin/infusional 5-FU/radiation therapy (RT) with or without subsequent esophageal resection in patients with localized esophageal cancer: a Minnie Pearl Cancer Research Network trial (abstract). J Clin Oncol 2005; 23: 4018.
5. Chiu PW, Chan AC, Leung SF, Leong HT, Kwong KH, Li MK, Au-Yeung AC, Chung SC, Ng EK: Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg 2005; 9: 794-802.
6. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000; 232: 225-232.
7. Law S, Wong KH, Kwok KF, Chu KM, Wong J: Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. Ann Surg 2004; 240: 791-800.
8. Steyerberg EW, Neville BA, Koppert LB, Lemmens VE, Tilanus HW, Coebergh JW, Weeks JC, Earle CC: Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 2006; 24: 4277-4284.
9. Graham AJ, Shrive FM, Ghali WA, Manns BJ, Grondin SC, Finley RJ, Clifton J: Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. Ann Thorac Surg 2007; 83: 1257-1264.
10. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084.
11. Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobsen A, Mantyla M, Modig H, Munck-Wikland E, Rosengren B, et al: Preoperative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992; 16: 1104-1109, discussion 1110.
12. Le Prise E, Etienne PL, Meunier B, Maddern G, Ben Hassel M, Gedouin D, Boutin D, Campion JP, Launois B: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994; 73: 1779-1784.
13. Apinop C, Puttisak P, Preecha N: A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994; 41: 391-393.
14. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337: 161-167.
15. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 305-313.
16. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-467.
17. Cao XF, He XT, Ji L, Xiao J, Lv J: Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Dis Esophagus 2009; 22: 477-481.
18. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005; 6: 659-668.
19. Lee JL, Park SI, Kim SB, Jung HY, Lee GH, Kim JH, Song HY, Cho KJ, Kim WK, Lee JS, Kim SH, Min YI: A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004; 15: 947-954.
20. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-1092.
21. Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Yokomakura N, Ishigami S, Owaki T, Aikou T: Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus 2006; 19: 468-472.
22. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
23. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721.
24. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Konigsrainer A, Budach W, Wilke H: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-856.
25. Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, Barbour AP, Gotley DC, Smithers BM: Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 2011; 47: 354-360.
26. Mariette CSJ, Maillard E, et al: Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase III trial FFCD 9901 (abstract). Proc Am Soc Clin Oncol 2010; 28(15 suppl):4005.
27. Carstens HMA, Friesland S, et al: A randomized trial of chemoradiotherapy versus surgery alone in patients with resectable esophageal cancer (abstract). J Clin Oncol 2007; 25: 4530.
28. Yu J, Ren R, Sun X, et al: A randomized clinical study of surgery versus radiotherapy in the treatment of resectable esophageal cancer (abstract). J Clin Oncol 2006; 24: 4013.
29. Courrech Staal EF, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H, van Sandick JW: Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg 2010; 97: 1482-1496.
30. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT: Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007; 109: 658-667.
31. Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P, Montemurro M, Schneider PM, Rauch D, Gautschi O, Mingrone W, Widmer L, Inauen R, Brauchli P, Hess V: Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II trial (SAKK 75/06). J Clin Oncol 2011; 29: 626-631.
32. De Vita F, Orditura M, Martinelli E, Vecchione L, Innocenti R, Sileni VC, Pinto C, Di Maio M, Farella A, Troiani T, Morgillo F, Napolitano V, Ancona E, Di Martino N, Ruol A, Galizia G, Del Genio A, Ciardiello F: A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer 2011; 104: 427-432.
33. Li G, Hu W, Wang J, Deng X, Zhang P, Zhang X, Xie C, Wu S: Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma. Int J Radiat Oncol Biol Phys 2010; 78: 1407-1412.
34. Hurt CN, Nixon LS, Griffiths GO, Al-Mokhtar R, Gollins S, Staffurth JN, Phillips CJ, Blazeby JM, Crosby TD: SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer 2011; 11: 466.
35. D'Journo XB, Michelet P, Dahan L, Doddoli C, Seitz JF, Giudicelli R, Fuentes PA, Thomas PA: Indications and outcome of salvage surgery for oesophageal cancer. Eur J Cardiothorac Surg 2008; 33: 1117-1123.
36. Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ, Weber WA: Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22: 900-908.
37. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA: Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 2011; 117: 4823-4833.
38. Lammering G, De Ruysscher D, van Baardwijk A, Baumert BG, Borger J, Lutgens L, van den Ende P, Ollers M, Lambin P: The use of FDG-PET to target tumors by radiotherapy. Strahlenther Onkol 2010; 186: 471-481.
39. Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R: Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 2006; 78: 236-244.
40. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174.
41. Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R: Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys 2012; 82: 468-474.
42. Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, Dong L, Zhu XR, Likhacheva A, Liao Z, Hofstetter WL, Ajani JA, Cox JD: Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys 2011; 81: 1336-1342.
43. Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA: Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 2012; 118: 2632-2640.
44. Ruppert BN, Watkins JM, Shirai K, Wahlquist AE, Garrett-Mayer E, Aguero EG, Sherman CA, Reed CE, Sharma AK: Cisplatin/irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol 2010; 33: 346-352.
45. Conroy T, Yataghene Y, Etienne PL, Michel P, Senellart H, Raoul JL, Mineur L, Rives M, Mirabel X, Lamezec B, Rio E, Le Prise E, Peiffert D, Adenis A: Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer 2010; 103: 1349-1355.
46. Conroy T, Galais MP, Raoul JC, Bouche O, Gourgou-Bourgade S, Douillard YV, Etienne PL, Boige V, Imartel-Lafay I, Michel P, Llacer-Moscardo P, Berille J, Bedenne L, Adenis A: Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): final results of the PRODIGE 5/ACCORD 17 trial (abstract). J Clin Oncol 2012; 30(suppl):LBA4003.